201 related articles for article (PubMed ID: 28544101)
1. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
3. Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center.
Oren D; Uriel M; Moeller CM; Valledor AF; DeFilippis EM; Lotan D; Colombo PC; Yuzefpolskaya M; Topkara VK; Clerkin KJ; Raikhelkar JK; Fried JA; Oh DKT; Bae D; Lin E; Theodoropoulos K; Naka Y; Takeda K; Choe J; Jennings DL; Majure D; Latif F; Sayer G; Uriel N
Clin Transplant; 2024 Mar; 38(3):e15251. PubMed ID: 38504576
[TBL] [Abstract][Full Text] [Related]
4. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
5. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
[TBL] [Abstract][Full Text] [Related]
6. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
[TBL] [Abstract][Full Text] [Related]
7. Use of belatacept in kidney transplantation: what's new?
Yakubu I; Moinuddin I; Gupta G
Curr Opin Organ Transplant; 2023 Feb; 28(1):36-45. PubMed ID: 36326538
[TBL] [Abstract][Full Text] [Related]
8. Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.
Petrossian G; Ortiz J; Ortiz AC; Addonizio K; Hsiao A; James R; Koizumi N; Patel S; Plews R
Transpl Immunol; 2023 Aug; 79():101857. PubMed ID: 37201797
[TBL] [Abstract][Full Text] [Related]
9. Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.
Anderson DJ; Lo DJ; Leopardi F; Song M; Turgeon NA; Strobert EA; Jenkins JB; Wang R; Reimann KA; Larsen CP; Kirk AD
Am J Transplant; 2016 May; 16(5):1456-64. PubMed ID: 26602755
[TBL] [Abstract][Full Text] [Related]
10. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.
Magua W; Johnson AC; Karadkhele GM; Badell IR; Vasanth P; Mehta AK; Easley KA; Newell KA; Rickert JB; Larsen CP
Transpl Infect Dis; 2022 Dec; 24(6):e13983. PubMed ID: 36321801
[TBL] [Abstract][Full Text] [Related]
11. Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future.
Kitchens WH; Larsen CP; Badell IR
Kidney Int Rep; 2023 Dec; 8(12):2529-2545. PubMed ID: 38106575
[TBL] [Abstract][Full Text] [Related]
12. Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation.
Johnson AC; Zhang J; Karadkhele G; Gragert L; Hertzberg V; Larsen CP
Am J Transplant; 2024 Feb; 24(2):260-270. PubMed ID: 37778459
[TBL] [Abstract][Full Text] [Related]
13. Infection in Patients on Belatacept Regimen After Kidney Transplant.
Moein M; Lui JJ; Li BW; Saidi R
Exp Clin Transplant; 2023 Oct; 21(10):801-806. PubMed ID: 37965954
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients.
Burghuber CK; Manook M; Ezekian B; Gibby AC; Leopardi FV; Song M; Jenks J; Saccoccio F; Permar S; Farris AB; Iwakoshi NN; Kwun J; Knechtle SJ
Am J Transplant; 2019 Mar; 19(3):724-736. PubMed ID: 30102844
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Randomized Controlled Trial of De Novo Belatacept-based Immunosuppression After Lung Transplantation.
Huang HJ; Schechtman K; Askar M; Bernadt C; Mitter B; Dore P; Goodarzi A; Yau S; Youssef JG; Witt CA; Byers DE; Vazquez-Guillamet R; Halverson L; Nava R; Puri V; Kreisel D; Gelman AE; Hachem RR
Transplantation; 2024 Mar; 108(3):777-786. PubMed ID: 37899481
[TBL] [Abstract][Full Text] [Related]
16. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
Cvetkovski F; Razavi R; Sellberg F; Berglund E; Berglund D
Am J Transplant; 2023 Oct; 23(10):1603-1611. PubMed ID: 37270108
[TBL] [Abstract][Full Text] [Related]
17. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
Gupta G; Womer KL
Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
[TBL] [Abstract][Full Text] [Related]
18. Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France.
Bertrand D; Brunel M; Lebourg L; Scemla A; Lemoine M; Amrouche L; Laurent C; Legendre C; Guerrot D; Anglicheau D; Sberro-Soussan R
Transpl Int; 2023; 36():11328. PubMed ID: 37554319
[TBL] [Abstract][Full Text] [Related]
19. Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts.
Bredewold OW; van Oeveren-Rietdijk AM; Florijn B; Rotmans JI; de Fijter JW; van Kooten C; van Zonneveld AJ; de Boer HC
Transpl Immunol; 2024 Feb; 82():101976. PubMed ID: 38199271
[TBL] [Abstract][Full Text] [Related]
20. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.
Stock PG; Mannon RB; Armstrong B; Watson N; Ikle D; Robien MA; Morrison Y; Odorico J; Fridell J; Mehta AK; Newell KA
Am J Transplant; 2020 Jun; 20(6):1668-1678. PubMed ID: 32039559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
